Blood–brain barrier dysfunction in the pathogenesis of major depressive disorder

S Wu, Y Yin, L Du - Cellular and molecular neurobiology, 2022 - Springer
Major depression represents a complex and prevalent psychological disease that is
characterized by persistent depressed mood, impaired cognitive function and complicated …

Considerations in the development of reversibly binding PET radioligands for brain imaging

VW Pike - Current Medicinal Chemistry, 2016 - ingentaconnect.com
The development of reversibly binding radioligands for imaging brain proteins in vivo, such
as enzymes, neurotransmitter transporters, receptors and ion channels, with positron …

Human iPSC-derived blood-brain barrier microvessels: validation of barrier function and endothelial cell behavior

RM Linville, JG DeStefano, MB Sklar, Z Xu, AM Farrell… - Biomaterials, 2019 - Elsevier
Microvessels of the blood-brain barrier (BBB) regulate transport into the brain. The highly
specialized brain microvascular endothelial cells, a major component of the BBB, express …

[HTML][HTML] Pleiotropic roles of ABC transporters in breast cancer

J He, E Fortunati, DX Liu, Y Li - International Journal of Molecular …, 2021 - mdpi.com
Chemotherapeutics are the mainstay treatment for metastatic breast cancers. However, the
chemotherapeutic failure caused by multidrug resistance (MDR) remains a pivotal obstacle …

Discovery of encequidar, first-in-class intestine specific P-glycoprotein inhibitor

MP Smolinski, S Urgaonkar, L Pitzonka… - Journal of Medicinal …, 2021 - ACS Publications
Many chemotherapeutics, such as paclitaxel, are administered intravenously as they suffer
from poor oral bioavailability, partly because of efflux mechanism of P-glycoprotein in the …

Imaging techniques to study drug transporter function in vivo

N Tournier, B Stieger, O Langer - Pharmacology & therapeutics, 2018 - Elsevier
Transporter systems involved in the permeation of drugs and solutes across biological
membranes are recognized as key determinants of pharmacokinetics. Typically, the action of …

Approaching Complete Inhibition of P-Glycoprotein at the Human Blood–Brain Barrier: An (R)-[11C]Verapamil PET Study

M Bauer, R Karch, M Zeitlinger… - Journal of Cerebral …, 2015 - journals.sagepub.com
As P-glycoprotein (Pgp) inhibition at the blood–brain barrier (BBB) after administration of a
single dose of tariquidar is transient, we performed positron emission tomography (PET) …

Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?

L Breuil, S Marie, S Goutal, S Auvity… - Journal of Cerebral …, 2022 - journals.sagepub.com
Only partial deficiency/inhibition of P-glycoprotein (P-gp, ABCB1) function at the blood-brain
barrier (BBB) is likely to occur in pathophysiological situations or drug-drug interactions. This …

Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib

S Goutal, M Gerstenmayer, S Auvity, F Caillé… - Journal of controlled …, 2018 - Elsevier
Overcoming the efflux mediated by ATP–binding cassette (ABC) transporters at the blood-
brain barrier (BBB) remains a challenge for the delivery of small molecule tyrosine kinase …

P-Glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-metoclopramide across the blood–brain barrier: a PET study on nonhuman primates

S Auvity, F Caillé, S Marie, C Wimberley… - Journal of Nuclear …, 2018 - Soc Nuclear Med
PET imaging using radiolabeled avid substrates of the ATP-binding cassette (ABC)
transporter P-glycoprotein (ABCB1) has convincingly revealed the role of this major efflux …